Photocure says BRAVO study shows Blue Light Cystoscopy nears 5-year cost neutrality

Powershares Exchange Traded Fd Tst Water Resource Portfolio

Powershares Exchange Traded Fd Tst Water Resource Portfolio

PHO

0.00
  • Photocure flagged new real-world evidence on Blue Light Cystoscopy that was presented at the American Urological Association’s 2026 annual meeting in Washington.
  • One study reported that Blue Light Cystoscopy improved early identification of high-risk non-muscle-invasive bladder cancer, which was associated with earlier use of guideline-aligned treatment choices in routine practice.
  • A separate cost and outcomes analysis found higher upfront care costs versus white light cystoscopy, with fewer recurrences narrowing the gap toward cost neutrality over five years.
  • The findings support the case for broader use of the technology in high-risk patients, with potential implications for utilization, treatment pathways, and long-term economics.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Photocure ASA published the original content used to generate this news brief via Cision (Ref. ID: 202605181100BITN____UKPR__EN_20260518-BIT-3619-0) on May 18, 2026, and is solely responsible for the information contained therein.

This page is machine-translated. Sahm tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation. *Disclaimer: The above content only represents the author's personal position and opinion and does not represent any position of Sahm Capital Financial Company and Sahm cannot confirm the authenticity, accuracy, and originality of the above content. Investors should consider the risks of investment products in light of their circumstances before making any investment decisions. When necessary, please consult a professional investment advisor. Sahm does not provide any investment advice, nor does it make any commitments and guarantees.